NOT MEDICAL ADVICE. No information on this site should be considered medical advice. Research peptides are not intended for human consumption — in-vitro lab use only. Consult a physician prior to introducing anything into the human body.
Peptide HubResearch Peptide Wiki
Support Us Join

Home/Categories/Weight Loss & Metabolic

Weight Loss & Metabolic

GLP-1 class agents, appetite regulators, insulin-sensitizing and energy-metabolism peptides studied for weight and metabolic research. 19 profiles

01

Adipotide

Investigational prohibitin-targeting pro-apoptotic peptide conjugate studied in obese mice and monkeys to reduce adipose vasculature; not tested in humans.

Read profile →02

Advanced Thermogenic Master Analogs

Marketing-style catalog label implying peptides that enhance thermogenesis; no defined compound exists under this name in the literature.

Read profile →03

AMPK & mTOR Balance Analogs

Catalog label implying peptides that modulate the AMPK/mTOR signaling balance; no specific compounds are characterized under this name.

Read profile →04

Amylin Analogs (Expanded)

Class listing for synthetic analogs of the pancreatic hormone amylin; pramlintide is the approved reference agent, while novel long-acting analogs are investigational.

Read profile →05

Autophagy Enhancer Peptide Analogs

Catalog category for peptides claimed to enhance autophagy; not a recognized compound class in the literature.

Read profile →06

C-Peptide Analogs

Synthetic peptides related to the proinsulin connecting peptide, whose native form has been studied as an adjunct in type 1 diabetes; analogs are undocumented.

Read profile →07

Cagrilintide

Long-acting synthetic amylin analog in clinical development for obesity, often studied with semaglutide as the combination referred to as CagriSema.

Read profile →08

Capstone Metabolic Regulator Analogs

Capstone-style marketing label implying broad metabolic regulation; no defined compound exists under this name in the literature.

Read profile →09

Energy Homeostasis Master Analogs

Master-style marketing label implying broad control of energy homeostasis; no defined compound exists under this name.

Read profile →10

FGF21 Analogs

Category of products sold as FGF21-related analogs; native FGF21 is real, but these specific items are undocumented.

Read profile →11

Mazdutide

Dual GLP-1/glucagon receptor agonist peptide in clinical development for obesity and type 2 diabetes.

Read profile →12

P-21

A catalog product label whose identity is unconfirmed; it overlaps with the well-known p21 cell-cycle protein but matches no documented peptide.

Read profile →13

PYY (Peptide YY) Analogs

PYY(3-36) is a real appetite-regulating hormone fragment, but this analog-class entry identifies no specific characterized product.

Read profile →14

Retatrutide

An investigational single peptide designed as a triple agonist of the GLP-1, GIP, and glucagon receptors for obesity and metabolic disease.

Read profile →15

Semaglutide

An approved GLP-1 receptor agonist with a fatty-acid modification for once-weekly dosing in type 2 diabetes and chronic weight management.

Read profile →16

SLU-PP-332

A synthetic small-molecule agonist of estrogen-related receptors, not a peptide; reported as an exercise mimetic in mice.

Read profile →17

Survodutide

An investigational dual glucagon and GLP-1 receptor agonist with reported phase 2 weight-loss and MASH data; not approved.

Read profile →18

Tirzepatide

An approved dual GIP and GLP-1 receptor agonist peptide for type 2 diabetes and obesity, given by once-weekly injection.

Read profile →19

Whole-Body Metabolic Orchestrator Analogs

A capstone vendor label describing an overarching concept, with no defined compound or peer-reviewed basis.

Read profile →